Face masks are still required to be worn while at the facility, even if you have been fully vaccinated. Thank you for your understanding!
CORONAVIRUS ALERT: WNY BloodCare is continually monitoring information during this outbreak. Please visit our News section for the latest updates
Spark Therapeutics is dedicated to understanding and advancing the science of gene therapy. As we all know, gene therapy is complex and can be challenging to explain. The patient advocacy team at Spark Therapeutics is committed to continually evaluating how best to unravel that complexity and provide comprehensive educational tools to help explain the science behind gene therapy research to the hemophilia community. That is the mission of HemophiliaForward.com, an educational website developed with the input of the patient community, which has been evolving in an aim to continue to answer some of the educational needs of the community.
Today we are excited to announce the launch of a new page dedicated to frequently asked questions (FAQs) about investigational gene therapy clinical trials for hemophilia. This page was created in response to the questions we were hearing from members of the hemophilia community. It’s an educational resource for people who are looking to learn more or are considering the decision to participate in an investigational gene therapy clinical trial for hemophilia. This is one more step in that hemophilia journey. We invite you to follow the link below to explore these FAQs.
If you don’t see a question or topic addressed that you think should be covered, there is a place to share your thoughts on the site. Spark Therapeutics will continue to expand this FAQ page and address other important topics about gene therapy research for hemophilia.